Celgene Corporation (CELG) Shares Sold by Biondo Investment Advisors LLC

Biondo Investment Advisors LLC reduced its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 141,822 shares of the biopharmaceutical company’s stock after selling 380 shares during the period. Celgene Corporation makes up 5.0% of Biondo Investment Advisors LLC’s portfolio, making the stock its 4th largest position. Biondo Investment Advisors LLC’s holdings in Celgene Corporation were worth $13,988,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Motco boosted its position in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the period. Carroll Financial Associates Inc. boosted its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. boosted its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the period. Reilly Financial Advisors LLC boosted its position in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 161 shares during the period. Finally, WealthTrust Arizona LLC boosted its position in Celgene Corporation by 26.1% in the first quarter. WealthTrust Arizona LLC now owns 1,213 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 251 shares during the period. 78.26% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ CELG) opened at 125.16 on Tuesday. Celgene Corporation has a 12-month low of $94.42 and a 12-month high of $127.64. The company has a market cap of $97.73 billion, a P/E ratio of 47.00 and a beta of 1.82. The firm’s 50 day moving average is $119.14 and its 200 day moving average is $119.67.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The company’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 earnings per share. Equities research analysts anticipate that Celgene Corporation will post $7.29 EPS for the current fiscal year.

WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/2654482/celgene-corporation-celg-shares-sold-by-biondo-investment-advisors-llc.html.

Several equities analysts recently issued reports on the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a research report on Wednesday, June 14th. BidaskClub raised Celgene Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. Cowen and Company reaffirmed an “outperform” rating and issued a $150.00 price objective on shares of Celgene Corporation in a research report on Wednesday, March 8th. Finally, Mizuho upped their price objective on Celgene Corporation from $130.00 to $134.00 and gave the company a “buy” rating in a research report on Thursday, June 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $139.49.

In other news, Director James J. Loughlin sold 9,250 shares of the business’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the sale, the director now owns 32,169 shares of the company’s stock, valued at $3,988,956. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders have sold 28,068 shares of company stock valued at $3,459,768 in the last three months. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CELG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.